GENE-THERAPEUTIC DNA VECTOR BASED ON THE GENE-THERAPEUTIC DNA VECTOR VTvaf17, CARRYING THE TARGET GENE CFTR, OR NOS1, OR AQ1, OR AQ3, OR AQ5, FOR TREATING DISEASES ASSOCIATED WITH THE NEED TO INCREASE THE LEVEL OF EXPRESSION OF THESE TARGET GENES, A METHOD FOR PRODUCING AND USING IT, ESCHERICHIA COLI SCS110-AF/VTvaf17-CFTR STRAIN, OR ESCHERICHIA COLI SCS110-AF/VTvaf17-NOS1, OR ESCHERICHIA COLI SCS110-AF/VTvaf17-AQ1, OR ESCHERICHIA COLI SCS110-AF/VTvaf17-AQ3, OR ESCHERICHIA COLI SCS110-AF/VTvaf17-AQ5, CARRYING A GENE-THERAPEUTIC DNA VECTOR, METHOD FOR PRODUCTION THEREOF, A METHOD FOR INDUSTRIAL PRODUCTION OF A GENE-THERAPEUTIC DNA VECTOR Russian patent published in 2019 - IPC C12N15/12 C12N15/53 A61K48/00 C12N1/21 C12N15/70 C12R1/19 

FIELD: biotechnology.

SUBSTANCE: invention relates to genetic engineering, biotechnology, medicine and represents a gene-therapeutic DNA vector based on the gene-therapeutic DNA vector VTvaf17, carrying the target CFTR gene, or NOS1, or AQ1, or AQ3, or AQ5, for treating diseases associated with the need to increase the level of expression of these target genes, which is a group of gene-therapeutic DNA vectors, each containing a coding part of at least one target gene selected from CFTR, or NOS1, or AQ1, or AQ3, or AQ5 , cloned into the VTvaf17 genotyping DNA vector, wherein the group of gene-therapeutic DNA vectors comprise a VTvaf17-CFTR gene vector of 7,606 base pairs, or VTvaf17-NOS1, having size of 7,468 base pairs, or VTvaf17-AQ1 with size of 3,982 base pairs, or VTvaf17-AQ3, size of 4,024 base pairs, or VTvaf17-Q5, size 3,943 base pairs, with nucleotide sequence SEQ ID No. 1, or SEQ ID No. 2, or SEQ ID No. 3, or SEQ ID No. 4, or SEQ ID No. 5, respectively, or a combination thereof.

EFFECT: invention allows higher expression of target genes.

16 cl, 18 dwg, 24 ex